A groundbreaking initiative from the Trump administration could revolutionize access to costly weight-loss drugs under ...

Eli Lilly and Company (NYSE: LLY) is one of the top most profitable NYSE stocks to buy now. On August 7, Leerink downgraded ...

Eli Lilly’s GIP/GLP-1 dual receptor agonist Mounjaro (tirzepatide) has demonstrated cardiovascular protection in a late-stage ...

China’s drugmakers are racing to roll out cheaper or more innovative alternatives. Read more at straitstimes.com. Read more ...

A transformative moment in the global fight against obesity has emerged with the announcement of positive topline results ...

Eli Lilly's pill, orforglipron, is a step closer to becoming the first needle-free alternative in the booming market for weight loss drugs.

Here are five oral obesity candidates that, according to Mizuho’s Graig Suvannavejh, could change the weight loss game.

Healthcare earnings update: 93% of sector firms have reported, highlighting robust revenue growth & few misses.